Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia
暂无分享,去创建一个
D. Niederwieser | C. Junghanss | M. Cross | H. Al-Ali | R. Krahl | G. Maschmeyer | N. Jaekel | Bin Li | E. Bach | Thao Tran | Thao Tran | Cuimin Ding | Cuiqiao Li | Hongjing Wang | Zhanjun Guo | D. Niederwieser | Michael Cross | Thao Tran | Christian Junghanss | Georg Maschmeyer | Michael Cross | Thao Tran | Georg Maschmeyer
[1] Pearlly Yan,et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. , 2012, Blood.
[2] M. Minden,et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Marcucci,et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. , 2012, Blood.
[4] T. Down,et al. Genome Wide Analysis of Acute Myeloid Leukemia Reveal Leukemia Specific Methylome and Subtype Specific Hypomethylation of Repeats , 2012, PloS one.
[5] A. Levis,et al. Azacitidine for the treatment of patients with acute myeloid leukemia , 2012, Cancer.
[6] D. Niederwieser,et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study , 2012, Leukemia & lymphoma.
[7] H. Kim,et al. DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome , 2011, Journal of Korean medical science.
[8] Lagadinou D. Eleni,et al. Challenges in Treating Older Patients with Acute Myeloid Leukemia , 2010, Journal of oncology.
[9] Helen Brady,et al. A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.
[10] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[12] F. J. Gonzalez,et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. , 2010, Blood.
[13] M. Schaefer,et al. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. , 2009, Cancer research.
[14] Chris A. Nasrallah,et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. , 2009, Blood.
[15] J. Issa,et al. Targeting DNA Methylation , 2009, Clinical Cancer Research.
[16] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[17] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[18] J. Issa,et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. , 2008, Blood.
[19] G. Mufti,et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine , 2007, Leukemia.
[20] U. Germing,et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.
[21] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[22] P. Sonneveld,et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial , 2007, British journal of haematology.
[23] M. Grever,et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.
[24] J. Issa,et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.
[25] Susan O'Brien,et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.
[26] F. Prósper,et al. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia , 2005, Oncogene.
[27] W. Farrar,et al. NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, But is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells , 2004, Cancer biology & therapy.
[28] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Grañena,et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Stone,et al. The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.
[31] J. Christman,et al. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.
[32] J. Holland,et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[34] J. Herman,et al. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.
[35] L H Li,et al. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.
[36] R. Mertelsmann,et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. , 2006, Haematologica.